GB2612481A - A novel medicament for immune modulation and treating chronic or hyper inflammation - Google Patents
A novel medicament for immune modulation and treating chronic or hyper inflammation Download PDFInfo
- Publication number
- GB2612481A GB2612481A GB2300774.3A GB202300774A GB2612481A GB 2612481 A GB2612481 A GB 2612481A GB 202300774 A GB202300774 A GB 202300774A GB 2612481 A GB2612481 A GB 2612481A
- Authority
- GB
- United Kingdom
- Prior art keywords
- use according
- medicament
- treatment
- anabasine
- immune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Present invention is a designation of a novel medicament for immune modulation and treating chronic or hyper inflammation. Its active ingredient is anabasine or its salt. It was designed for example to treat some of auto immune diseases permanently such as asthma and atopic dermatitis by one medication course, to stop the progression and development of diabetes type 2 in diabetics and restoring their blood sugar to normal with respect to administration in the disease early stages, to prevent the incidence and development of autoimmune Diabetes Type 1 resulted from T cell-mediated damage of pancreatic β-cells and loss of insulin production. Further, it plays a pivotal and protective role in treating hazardous infections caused by diverse pathogens to promote and accelerate recovery, including COVID -19 with its variants.
Claims (1)
- Claims1- Use of anabasine in the preparation of a human medicament for immune modulation and treating chronic or hyper inflammation .2- Use of anabasine in the preparation of a human medicament for the innate immune modulation and treating chronic or hyper inflammation .3- The use according to either claim 1 or 2 is for the treatment of auto immune diseases and as an immune modulator medicament for these diseases .4- The use according to either claim 1 or 2 is for the treatment of all infections types as microbial infections , protozoan infections , prion disease and other infections including those caused by ectoparasites , as an immune modulator and pivotal / protective treatment .5- The use according to either claim 1 or 2 is for inhibiting or controlling hypercytokinemia induced by infectious or non-infectious etiologies as an immune modulator .6- The use according to either claim 1 or 2 is for the therapeutic treatment of diabetes type 2 , stopping the progression and development of diabetes type 2 in diabetics and restoring their blood sugar to normal with respect to the administration in disease first / early stages as an immune modulator .7- The use according to either claim lor 2 is a treatment for preventing the incidence and development of autoimmune Diabetes Type 1 , particularly which resulted from T cell- mediated damage of pancreatic b-cells and loss of insulin production as an immune modulator .8- The use according to either claim 1 or 2 is for the therapeutic treatment of asthma types, chest allergy and atopic dermatitis permanently .9- The use according to either claim 1 or 2 is for the therapeutic treatment of chronic systemic inflammation , systemic inflammation or systemic inflammation response syndrome particularly which due to internal (genetic mutations/variations) factors and as an immune modulator medicament .10- The use according to claim 1 or 2 or 3 or 4 or 5 or 9 wherein subject in need to such treatment is an animal .11- The pharmaceutical composition of the said medicament according to any preceding claim is comprising of anabasine as an active ingredient or its salt and a pharmacologically acceptable excipient , diluent or carrier.12- The pharmaceutical composition of the said medicament according to claims from 1 to 10 is comprising of anabasine as an active ingredient at concentration of anabasine from 0.01 mg /kg : 3.5 mg / kg of body weight or its salt and a pharmacologically acceptable excipient , diluent or carrier.13- The use according to any preceding claim wherein said medicament with said pharmaceutical composition is for systemic , local or topical administration .14- The use according to any preceding claim wherein said medicament with said pharmaceutical composition further comprises or may be co-administered with an existing therapeutic agent for achieving , treating or managing any said purposes , diseases or conditions in claims 1 to 9 .
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EG2020060768 | 2020-06-09 | ||
| PCT/EG2021/000016 WO2021249608A2 (en) | 2020-06-09 | 2021-06-07 | A novel medicament for immune modulation and treating chronic or hyper inflammation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB202300774D0 GB202300774D0 (en) | 2023-03-08 |
| GB2612481A true GB2612481A (en) | 2023-05-03 |
Family
ID=78845336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB2300774.3A Withdrawn GB2612481A (en) | 2020-06-09 | 2021-06-07 | A novel medicament for immune modulation and treating chronic or hyper inflammation |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU2021286756A1 (en) |
| GB (1) | GB2612481A (en) |
| WO (1) | WO2021249608A2 (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5741802A (en) * | 1992-08-31 | 1998-04-21 | University Of Florida | Anabaseine derivatives useful in the treatment of degenerative diseases of the nervous system |
| WO1999010338A2 (en) * | 1997-08-29 | 1999-03-04 | University Of Florida | Benzylidene- and cinnamylidene-anabaseines as neuronal nicotinic alpha-7 receptor agonists |
| US20050288333A1 (en) * | 2004-06-08 | 2005-12-29 | Kem William R | Controlling angiogenesis with anabaseine analogs |
| US20070232651A1 (en) * | 2006-01-26 | 2007-10-04 | Habgood Gregory J | Novel anabaseine derivatives, pharmaceutical compositions and methods of use thereof |
| US9387201B2 (en) * | 2011-08-29 | 2016-07-12 | Rcp Development, Inc. | Methods of providing anti-inflammation support |
| US20180139961A1 (en) * | 2016-11-20 | 2018-05-24 | Iowa State University Research Foundation, Inc. | (s)-5-ethynyl-anabasine, derivatives thereof, and related compositions and methods of making and using |
| WO2019202396A1 (en) * | 2018-04-16 | 2019-10-24 | Poviva Tea, Llc | Compositions infused with nicotine compounds and methods of use thereof |
-
2021
- 2021-06-07 GB GB2300774.3A patent/GB2612481A/en not_active Withdrawn
- 2021-06-07 AU AU2021286756A patent/AU2021286756A1/en not_active Abandoned
- 2021-06-07 WO PCT/EG2021/000016 patent/WO2021249608A2/en not_active Ceased
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5741802A (en) * | 1992-08-31 | 1998-04-21 | University Of Florida | Anabaseine derivatives useful in the treatment of degenerative diseases of the nervous system |
| WO1999010338A2 (en) * | 1997-08-29 | 1999-03-04 | University Of Florida | Benzylidene- and cinnamylidene-anabaseines as neuronal nicotinic alpha-7 receptor agonists |
| US20050288333A1 (en) * | 2004-06-08 | 2005-12-29 | Kem William R | Controlling angiogenesis with anabaseine analogs |
| US20070232651A1 (en) * | 2006-01-26 | 2007-10-04 | Habgood Gregory J | Novel anabaseine derivatives, pharmaceutical compositions and methods of use thereof |
| US9387201B2 (en) * | 2011-08-29 | 2016-07-12 | Rcp Development, Inc. | Methods of providing anti-inflammation support |
| US20180139961A1 (en) * | 2016-11-20 | 2018-05-24 | Iowa State University Research Foundation, Inc. | (s)-5-ethynyl-anabasine, derivatives thereof, and related compositions and methods of making and using |
| WO2019202396A1 (en) * | 2018-04-16 | 2019-10-24 | Poviva Tea, Llc | Compositions infused with nicotine compounds and methods of use thereof |
Non-Patent Citations (2)
| Title |
|---|
| E. SHULTSA et al., "Anabasine as a Precursor for the Synthesis of Potential Agonists of Neuronal Acetylcholine Receptors E.", Doklady Chemistry,2007, Vol. 413, Part 1, pp. 59-63. Abs., page 59, compound IV * |
| Ya. Lukomskaya et al. CHOLINERGIC EFFECTIVENESS OF ANABASINE DERIVATIVES N."I. M. Sechenov Institute of Evolutionary Physiology and Biochemistry, Academy of Sciences of the USSR, Leningrad", Institute of National Economy, Tashkent. Translated from Khimiko-farmatsevticheskii Zhumal, Vol. 24, No.7, pp * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021249608A3 (en) | 2022-02-03 |
| AU2021286756A1 (en) | 2023-03-23 |
| WO2021249608A2 (en) | 2021-12-16 |
| WO2021249608A4 (en) | 2022-04-07 |
| GB202300774D0 (en) | 2023-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Auerbach et al. | Single-dose intravenous iron for iron deficiency: a new paradigm | |
| EP2635269B1 (en) | A combination composition | |
| RU2012148710A (en) | ORGANIC COMPOUND FOR USE IN TREATMENT OF LIVER CANCER | |
| JP2018513188A5 (en) | ||
| JP2012082219A (en) | Treatment of infectious disease | |
| JP2017514911A5 (en) | ||
| Lin | Desensitization in the management of vancomycin hypersensitivity | |
| Bossé et al. | Severe anaphylaxis caused by orally administered vancomycin to a patient with Clostridium difficile infection | |
| Belchí-Hernández et al. | Management of adverse reactions to prophylactic trimethoprim-sulfamethoxazole in patients with human immunodeficiency virus infection | |
| US20190070131A1 (en) | Sublingual Epinephrine Tablets | |
| GB2612481A (en) | A novel medicament for immune modulation and treating chronic or hyper inflammation | |
| WO2022039619A1 (en) | Antiviral agent for combined therapy of covid-19 (sars-cov-2) | |
| Oh et al. | Safety and efficacy of conversion from twice-daily tacrolimus to once-daily tacrolimus one month after transplantation: randomized controlled trial in adult renal transplantation | |
| Abrams-Downey et al. | Investigational therapies for the treatment of COVID-19: updates from ongoing clinical trials | |
| Brahmantya et al. | COVID-19 pharmacological treatment at the Udayana University Hospital in april-may 2020 | |
| Kim et al. | Hypersensitivity reaction to intravitreal clindamycin therapy | |
| Cheesman | Sickle cell disease: symptoms, complications and management | |
| Donnelly et al. | Overview of selected novel drugs approved in 2018 | |
| Sathaporn et al. | A Rare Cause of Refractory Vasodilatory Shock Due to Calcium Channel Blocker Toxicity from Drug-Drug Interaction Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) And Manidipine | |
| Fattizzo et al. | Monitoring of Patients with Autoimmune Cytopenias during Sars-Cov-2 Vaccination Campaign: The Experience of a Reference Center | |
| Pico-Picos et al. | British Journal of Heart Diseases | |
| 高気圧酸素療法で治療した犬の難治性創傷 | A non-healing wound in a dog treated with hyperbaric oxygen therapy | |
| Barret | Vancomycin acute anaphylactoid reaction in a paediatric burn | |
| Yeremenchuk | Prevention of the development of adverse reactions in the treatment of tuberculosis in combination with diabetes mellitus | |
| Attacks | Is Parvovirus B19 Related to Rheumatism in Children? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |